Alcon to acquire ESBATech for up to $589 million
Alcon is to buy ESBATech, a private Swiss biotechnology company focused on antibody fragments, for up to $589 million.
Alcon is to buy ESBATech, a private Swiss biotechnology company focused on antibody fragments, for up to $589 million.